Antigenics Inc.

Since joining Antigenics in 2003, Ms. Sharp has been a member of the senior management team, managing strategic planning, investor relations, and financing and acquisition transactions. Prior to this, she was director of strategic planning at Elan Corporation, plc., where she served as chief of staff to the chairman of the board during the restructuring process and drove to completion a number of strategic corporate and financial transactions. Ms. Sharp was previously a management consultant at McKinsey & Company, specializing in pharmaceuticals and medical devices. She has also worked in investment banking at Goldman, Sachs & Company, primarily in the health care field. Ms. Sharp received her BA and MBA from Harvard University.

Renu Gupta, M.D., Executive Vice President Development & Chief Medical Officer. Renu joins Transave from Antigenics, Inc., where she was Senior Vice President of Development, advancing its immunotherapy and small molecule pipeline for Oncology and Infectious Diseases. Prior to that, she served at Novartis as Vice President and Head of U.S. Clinical Research and Development and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research. Renu also spent two years at Covance as Vice President and Head of Medical, Safety and Therapeutics, and almost 10 years at Bristol-Myers Squibb, where she was responsible for clinical research, business development and global development and marketing strategy. Renu received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at Albert Einstein Medical Center and the University of Pennsylvania's Children's Hospital of Philadelphia. Her work has been published in leading peer-reviewed journals, including the Journal of Infectious Diseases and she has been active in numerous relevant academic and professional societies such as the Infectious Disease Society of America and the American Academy of Pediatrics.

Deanna M. Petersen is a broadly skilled senior executive who brings more than 14 years of worldwide business development experience to Antigenics. Ms. Petersen is responsible for all licensing opportunities for the company, and provides leadership in strategic planning, global business development, contract negotiation and intellectual property development. Formerly, Ms. Petersen was vice president of business development at Coley Pharmaceutical Group, where she was part of the core executive management team. Ms. Petersen helped build Coley from conception into a rapidly growing enterprise. In 2001, she structured and negotiated the fourth largest product licensing deal in the industry that year with Aventis Pharmaceuticals for first-in-class asthma and allergic rhinitis products based on Coley’s novel CpG immune technology. Prior to Coley, Ms. Petersen worked at the University of Iowa as director of technology transfer. She also conducted research for several years at the Howard Hughes Medical Institute. She has served on the board of directors for the Boston chapter of the Healthcare Businesswomen’s Association and on the board of directors for both the Iowa Biotechnology Association and the Iowa City Community School District Foundation. She has also held positions on the State of Iowa’s marketing and biotechnology advisory committees. Ms. Petersen received her bachelor’s degree in biology from Iowa State University and an MBA from the University of Iowa.

John Cerio has more than 15 years of experience as a human resources executive in the pharmaceutical and biotechnology industry. He spent nine years at Bristol-Myers Squibb, where he held a series of key leadership positions in corporate staff and in the worldwide medicines business. John led HR for Bristol’s oncology and immunology division, and established the organizational development function for its US medicines business, focused on building world-class capability in sales force organization design, operational effectiveness, staffing, development and compensation. In addition, he developed and implemented state-of-the-art practices in leadership and organization development, talent acquisition and retention, incentive systems and change management. Most recently John was vice president of human resources for Perkin Elmer Global Life Sciences. While at Perkin Elmer, John played a key leadership role in integrating more than $1 billion in strategic acquisitions, which positioned Perkin Elmer as the third largest drug discovery tools and technology company in the world. John holds a bachelor’s degree in industrial and labor relations from Cornell University, and a master’s degree in organizational psychology from Columbia University.

Karen Higgins Valentine is Vice President and General Counsel of Antigenics, Inc. Since joining Antigenics in 2004, Ms. Valentine has played an integral role in developing and managing the legal department, advising colleagues on key legal issues throughout the organization, and participating in strategic planning. She is a member of the Executive Management, and also serves as Secretary and Compliance Officer of the company. Prior to joining Antigenics, Ms Valentine was an associate in the biotechnology practice of Palmer & Dodge LLP (now Edwards, Angell, Palmer & Dodge LLP). While at the law firm, she provided corporate law services to a broad range of both public and private corporations, and developed an expertise in the areas of licensing and strategic collaborations. Ms Valentine graduated cum laude with a bachelor's degree in neuroscience from Colgate University, and received her law degree, magna cum laude, from Boston University School of Law. Prior to attending law school, Ms. Valentine was an excess umbrella underwriter for Chubb Group of Insurance Companies. Ms. Valentine has been recognized as a "Rising Star Super Lawyer" by Boston Magazine.

Ms. Kerry Wentworth is Vice President, Clinical Operations and Regulatory Affairs at Antigenics Inc., a biotechnology company with a late-stage development focus on an autologous therapeutic cancer vaccine. In this capacity, she is responsible for the execution of all phases of clinical development and defining associated regulatory strategy. Ms. Wentworth has over twelve years of global regulatory experience supporting the development, global licensing and post-marketing activities associated with multiple drug and biological products. Prior to joining Antigenics in 2004, she worked for a number of biotechnology companies including Genelabs Technologies, Shaman Pharmaceuticals and Genzyme Corporation. As part of her professional experience, she has also been responsible for other key functional areas including quality assurance and clinical compliance. Ms. Wentworth received a BS in pre-veterinary medicine from the University of New Hampshire.

Since joining Antigenics as a Scientist in 2001, Steve has held several positions of increasing responsibility. He has played a key role in supporting the clinical development of Antigenics lead immunotherapeutic Oncophage, defining the strategies for its manufacture, characterization, and release. In his current role as Vice President of Manufacturing, Process & Analytical Technologies, Steve oversees the manufacture of Antigenics' clinical products, aligned external contract manufacturing and the transfer of technology from research into development. Prior to joining Antigenics, he was with Genetics Institute (now Wyeth) from 1998 - 2001. Steve received his B.Sc., with first class honors, from the University of Queensland and his Ph.D. in Biochemistry and Molecular Biology from the University of Melbourne. Following his Ph.D, Steve completed a Howard Hughes fellowship at Brandeis University.

Sunny Uberoi joined Antigenics as the vice president of corporate communications in March 2002. He has more than 17 years of communications, marketing and sales experience in the pharmaceutical industry. From July 2002 through December 2003, Mr. Uberoi was responsible for crisis management at Elan Corporation, where he worked exclusively with the media, successfully improving the company’s reputation and image. Prior to his work at Antigenics and Elan, Mr. Uberoi was a cofounder of The Remedy, a London health care agency serving companies such as GlaxoSmithKline, Pharmacia and Schering-Plough. Mr. Uberoi has extensive experience in public and professional relations, lobbying, crisis management, government relations and prelaunch communication programs for innovative, first-to-market products. Mr. Uberoi has successfully raised the profile of biotech companies, including their pipeline and senior management. In these roles he has worked extensively with international journalists as well as thought leaders and patient advocacy groups. Mr. Uberoi has held marketing and sales positions at Johnson & Johnson and Merck KgaA. He received a bachelor’s degree in economics from Manchester Metropolitan University and a master’s degree in marketing from the University of Manchester Institute of Science and Technology.

Array

Dr. Pramod Srivastava is Professor of Immunology at the University of Connecticut School of Medicine, where he is also Director of the Center for Immunotherapy of Cancer and Infectious Diseases. He holds the Physicians Health Services Chair in Cancer Immunology at the University. Professor Srivastava is the Scientific Founder of Antigenics. He serves on the Scientific Advisory Council of the Cancer Research Institute, New York, and was a member of the Experimental Immunology Study Section of the National Institutes of Health of the U.S. Government (1994-1999). He serves presently on the Board of Directors of two privately held companies: Ikonisys (New Haven, Conn.) and CambriaTech (Lugano, Switzerland). In 1997, he was inducted into the Roll of Honor of the International Union Against Cancer and was listed in Whoi s Who in Science and Engineering. He is among the 20 founding members of the Academy of Cancer Immunology, New York. Dr. Pramod Srivastava obtained his bachelor's degree in biology and chemistry and a masteri s degree in botany (paleontology) from the University of Allahabad, India. He then studied yeast genetics at Osaka University, Japan. He completed his Ph.D. in biochemistry at the Center for Cellular and Molecular Biology, Hyderabad, India, where he began his work on tumor immunity, including identification of the first proteins that can mediate tumor rejection. He trained at Yale University and Sloan-Kettering Institute for Cancer Research. Dr. Srivastava has held faculty positions at the Mount Sinai School of Medicine and Fordham University in New York City.

Ronald M. Bukowski is the director of the experimental therapeutics program of the Cleveland Clinic Taussig Cancer Center and a professor of medicine at the Cleveland Clinic Foundation Lerner College of Medicine of Case Western Reserve University. He attended Northwestern University School of Medicine, and completed his training in internal medicine and medical oncology at the Cleveland Clinic Foundation. He is an international opinion leader in the biology and therapy of renal cell carcinoma, and the medical director of the Kidney Cancer Association.

Array

Dr. Larry W. Kwak received his MD and PhD in tumor cell biology from Northwestern University Medical School. After completing clinical training in internal medicine and medical oncology at Stanford University, he was recruited to the Biological Response Modifiers Program of the National Cancer Institute in 1992. In 1996, he was appointed head of the vaccine biology section at the National Institutes of Health (NIH), then was recruited to M. D. Anderson Cancer Center in 2004, where is he currently the Chairman of the department of lymphoma and myeloma, as well as the Associate Director of the Center for Cancer Immunology Research. Dr. Kwak is also the incumbent of the Moshe Talpaz Endowed Chair in Immunology at M. D. Anderson Cancer Center. Dr. Kwak has served on the program committees for the American Society of Hematology, the American Society of Clinical Oncology (ASCO), and the NIH Experimental Immunology Study Section. He is also a past recipient of the ASCO Young Investigator Award. He has served on the editorial board of the scientific journal Blood and on the scientific advisory board of the Multiple Myeloma Research Foundation. Dr. Kwak's translational scientific and clinical interests span tumor immunology, cancer vaccines, adoptive T-cell immunotherapy, and clinical management of lymphomas and myelomas. He has pioneered use of patient-specific vaccines as treatment against human lymphomas and has served as principal investigator of a multicenter Phase 3 randomized clinical trial of lymphoma vaccination. He is frequently invited to speak at national and international scientific meetings. He has published in journals such as Science, Nature Medicine, New England Journal of Medicine and The Lancet.

Array

Jo-Dee has over 20 years of experience in the design and implementation of integrated compensation strategies including the assessment and development of executive total compensation plans, sales and management incentive plans, equity-based pay programs and market/competency based salary systems. Jo-Dee is highly experienced in developing competency models used in performance management, selection, workforce planning and compensation programs. She also has extensive experience in the development and communication of employee benefit programs and implementation of HRM Systems. Jo-Dee is a specialist in the biopharmaceutical industry having worked with companies across the full range of sizes and product stages such as Genzyme, Biogen Idec, Antigenics, Hypnion, and Alnylam Pharmaceuticals. She also has in-depth experience in the financial services, retail and high technology industries, and in working with companies to implement acquisitions and mergers. Jo-Dee has been actively involved with steering committees for key national and regional surveys. She has made numerous professional presentations, particularly on the design of incentives and broad-based stock plans. Jo-Dee was a recipient of a Lifetime Achievement Award from the WorldatWork in 1997. She has degrees from Mount Holyoke College and Harvard University.

Highly regarded as an international expert in cancer immunotherapy and research, Dr. Kirkwood founded the University of Pittsburgh Cancer Institute’s (UPCI) Medical Oncology Division and the institute’s Clinical Investigation Program. He is currently director of the Melanoma Center at UPCI and also professor and vice chairman for clinical research in the university’s department of medicine. Dr. Kirkwood’s research concentrates on regional, national and international investigations of new biological and cytotoxic therapy for melanoma and other refractory tumors. He is largely responsible for making the UPCI Melanoma Center a national reference for studies of new drug and biological interventions in that cancer. He is a leader in laboratory and clinical studies across the spectrum of the disease.

Dr. Rothenberg is Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center and Professor of Medicine at Vanderbilt University Medical Center, in Nashville, Tennessee. He is also a medical oncologist with appointments at the Vanderbilt University Medical Center and the Department of Veterans Affairs Medical Center. Dr. Rothenberg is the Director of the Phase I Drug Development Program at Vanderbilt-Ingram Cancer Center and he serves on a number of committees including the Vanderbilt-Ingram Cancer Center Gastrointestinal Cancer SPORE Executive Committee and Lung Cancer SPORE Steering Committee, the Clinical Cancer Research Committee for the American Association for Cancer Research, and the Medical Oncology Committee for the American College of Surgeons. He also serves on the editorial boards of seven peer-reviewed journals and has authored over 100 scientific and clinical publications.

Brian Corvese is President and Founder of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management, a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the board of directors of the National Telecommunications Corporation, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.

Alastair J. J. Wood has been a director since 2004. Dr. Wood is an associate dean, attending physician and tenured professor of medicine and pharmacology at Vanderbilt Medical School in Nashville, Tenn., where he has been a faculty member for more than 20 years. A 2002 suggested nominee for commissioner of the US Food and Drug Administration (FDA), Dr. Wood served as a member of the FDA’s cardiovascular and renal advisory committee and serves on the agency’s nonprescription drug advisory committee, which he currently chairs. He is currently chair of the nonprescription drug advisory committee. He has also been a member and chairman of the National Institutes of Health study sections, and served in a similar capacity for various philanthropic grant-giving bodies, having acted as consultant to several pharmaceutical companies, investors, venture capital funds and major academic institutions. Dr. Wood was most recently the drug therapy editor of The New England Journal of Medicine from 1992 through 2004, and is on the editorial boards of The New England Journal of Medicine and Clinical Pharmacology and Therapeutics. He is a member of many societies and has received numerous honors, including election to membership of The American Association of Physicians, The American Society for Clinical Investigation, honorary fellowship of the American Gynecological and Obstetrical Society, and fellowships of The American College of Physicians, The Royal College of Physicians of London and The Royal College of Physicians of Edinburgh. Dr. Wood received his medical degree from St. Andrew’s University and Dundee Medical School in Scotland.

Array

John N. Hatsopoulos is chief executive officer of American DG Energy Inc. Headquartered in Waltham, Massachusetts, American DG Energy is the leading on-site utility offering electricity, heat, hot water and cooling to commercial, institutional and industrial facilities. Mr. Hatsopoulos is also chief executive officer of Tecogen Inc., a leading manufacturer of natural gas, engine-driven commercial and industrial cooling and cogeneration systems. In addition, Mr. Hatsopoulos is chairman of GlenRose Instruments Inc., a company that provides radiological and environmental services, as well as managing partner of Alexandros Partners LLC, a financial advisory firm. John Hatsopoulos is one of the founders of Thermo Electron Corp. (currently Thermo Fisher Scientific) and the retired president and vice chairman of the board of directors. Thermo Fisher Scientific is a leading provider of analytical and monitoring instruments used in a broad range of applications, from life sciences research to telecommunications, food, drug and beverage production. Mr. Hatsopoulos joined Thermo Electron as purchasing agent in 1956; in 1963 he became president of the company’s metals division, and was named vice president in 1970. Seven years later, he was appointed vice president of corporate strategy, handling acquisitions, financial and investor relations, and corporate investments. Mr. Hatsopoulos became senior vice president of Thermo Electron in 1984, and executive vice president of the company in 1986. In 1988, he was appointed chief financial officer and executive vice president of Thermo Electron, and was named president in 1997. Also in 1997, he was elected to the board of directors of Thermo Electron. He served as vice president and chief financial officer for Thermo Electron and all of its public subsidiaries from 1988 until 1998. John Hatsopoulos innovated and implemented numerous financial strategies that became the focus of worldwide interest. His spinout strategy resulted in 24 public companies and Thermo Electron and its subsidiaries were able to raise close to $5 billion of capital. Mr. Hatsopoulos graduated from Athens College in Athens, Greece, in 1953. He holds a BS in history and mathematics from Northeastern University, together with honorary doctorates in business administration from Boston College and Northeastern University. He served on the board of directors of the American Stock Exchange from 1994 through 2000 and the AMEX Nominating Committee from 1990 to 1994. He is currently a member of the board of directors of TEI BioSciences Inc., Antigenics Inc. and AmericanCare Source Holdings Inc., and a “Member of the Corporation” for Northeastern University.

Margaret M. (Peggy) Eisen has been a board member since 2003. Ms. Eisen is managing director of marketing and communications for CFA Institute. Ms. Eisen directs CFA Institute efforts to protect and build the CFA brand and to ensure that CFA Institute is recognized as the global leader for education and ethics in the profession, supporting the well respected CFA charter as well as the CFA Centre for Financial Market Integrity. She directly oversees marketing and external communications, including outreach and public awareness. Ms. Eisen has more than 25 years of investment industry experience. Prior to joining CFA Institute, Ms. Eisen was the chief executive officer and chief investment officer of EAM International LLC, which she founded to provide corporate finance and asset management services to entrepreneurs and wealthy individuals. Before forming EAM International, Ms. Eisen was managing director, North American equities, for General Motors Investment Management Corp. In that role she was responsible for portfolios of publicly traded and private equity. Currently, she is a member of the board of trustees of the Columbia Acorn Family of mutual funds of Wanger Asset Management Fund. She is also a member of the investment committee of the board of trustees of Smith College. Ms. Eisen previously served as chair of the Institute for Financial Markets. Ms. Eisen received her AB degree from Smith College, an MEd from Lesley College, and earned an MBA with distinction at Babson College. She is a chartered financial analyst.

Mark Kessel has been a director since 2003. Mr. Kessel is chief executive officer and managing director of Symphony Capital LLC. Symphony Capital manages a private equity fund that invests in the clinical development of biopharmaceutical products, and has served in such position since he cofounded the company in 2002. From 1979 to 2001, Mr. Kessel was a partner at the international law firm of Shearman & Sterling and served as the firm’s managing partner from 1990 to 1994. Mr. Kessel received a bachelor’s degree in economics from the City College of New York and a law degree from Syracuse University.

Array

Array